Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 26, 2026, reports a significant regulatory milestone for its investigational drug, bepirovirsen. The filing announces that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted a New Drug Application (NDA) for bepirovirsen as a potential first-in-class treatment for chronic hepatitis B (CHB).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused exclusively on a regulatory development and clinical trial status.
Material Changes and Developments
- Regulatory Acceptance: Japan's MHLW accepted the NDA for bepirovirsen, marking the first regulatory filing globally for this asset.
- Expedited Review: The submission benefits from SENKU designation, granted in August 2024, which enables an expedited review process due to the drug's innovation and potential to address high unmet medical need.
- Clinical Evidence: The submission is supported by positive results from the pivotal Phase III B-Well 1 and B-Well 2 trials, which demonstrated statistically significant and clinically meaningful functional cure rates compared to standard of care alone.
Outlook, Risks, and Management Commentary
Management Commentary: GSK highlights that chronic hepatitis B affects nearly one million people in Japan and over 250 million globally. Current standard therapies often require lifelong treatment with low functional cure rates (typically 1%). Bepirovirsen, a triple-action antisense oligonucleotide (ASO), aims to achieve functional cure by inhibiting viral replication and stimulating the immune system.
Future Steps: Data from the B-Well trials are anticipated to be presented at a congress and submitted for peer-reviewed publication in 2026. The drug is also being evaluated as a backbone therapy for future sequential treatment strategies.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q4 2025 results. Bepirovirsen is currently not approved anywhere in the world.
Key Facts for Investor Verification
- Verify the specific functional cure rates and safety profile details from the B-Well 1 and B-Well 2 Phase III trials once published in peer-reviewed journals.
- Monitor the timeline for the MHLW's final decision on the NDA, given the SENKU expedited designation.
- Assess the potential market size and reimbursement landscape for bepirovirsen in Japan and other regions where regulatory filings may follow.
- Review GSK's broader pipeline and financial impact projections in upcoming quarterly earnings reports, as this filing contains no financial figures.